Raptor Pharmaceutical Inc. (RPTP) Announces Full Enrollment Of Phase 2b Trial Of RP103 For Non-Alcoholic Fatty Liver Disease In Children
1/13/2014 9:52:54 AM
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target.
Help employers find you! Check out all the jobs and post your resume.
comments powered by